The trial is expected to begin in early third quarter of 2026.

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

The Boston-based biotech sold more stock than originally planned at $18 a share, giving it a market value of $1.1 billion

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9...

PureTech Health (NASDAQ:PRTC) used its annual results call to outline a refined operating strategy centered on a leaner corporate structure, earlier formation of “founded entities,” and an increased emphasis on returning capital to shareholders when significant inflows occur. Chief Executive Office

Key Insights Significantly high institutional ownership implies PureTech Health's stock price is sensitive to their...

PureTech Health (PRTC) said Monday that it completed the end-of-phase 2 meeting with the US Food and

PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.